

Figure S1: Effects of EPT therapy on osteoporosis-related traits across *VDR* genotypes. FBMD - femoral neck BMD, LBMD - lumbar spine BMD, bALP – bone isoenzyme of alkaline phosphatase, OC – osteocalcin, β-CTx - BetaCrosslaps, sCa - serum calcium, sP - serum phosphate, P values determine significant difference (***P<0.001; **P<0.01, *P<0.05).



Figure S2: Effects of ibandronate therapy on osteoporosis-related traits across *VDR* genotypes. FBMD - femoral neck BMD, LBMD - lumbar spine BMD, bALP – bone isoenzyme of alkaline phosphatase, OC – osteocalcin, β-CTx - BetaCrosslaps, sCa - serum calcium, sP - serum phosphate, P values determine significant differences (***P<0.001; **P<0.01, *P<0.05).



Figure S3: Effects of raloxifene therapy on osteoporosis-related traits across *VDR* genotypes. FBMD - femoral neck BMD, LBMD - lumbar spine BMD, bALP – bone isoenzyme of alkaline phosphatase, OC – osteocalcin, β-CTx - BetaCrosslaps, sCa - serum calcium, sP - serum phosphate, P values determine significant differences (***P<0.001; **P<0.01, *P<0.05).